Gene-therapy vectors for treating cardiomyopathy
The present invention relates to a gene therapy vector which is useful in the treatment or prevention of hypertrophic cardiomyopathy in a subject in need thereof. The gene therapy vector of the invention comprises a nucleic acid sequence encoding a cardiac sarcomeric protein and a cardiomyocyte-specific promoter which is operably linked to said nucleic acid sequence. The invention furthermore relates to a cell which comprises the gene therapy vector. Pharmaceutical compositions which comprise the gene therapy vector and/or a cell comprising said vector are also provided. In another aspect, the invention relates to a method for treating or preventing hypertrophic cardiomyopathy in a subject by introducing the gene therapy vector of the invention into a subject in need of treatment.
1. A method of treating hypertrophic cardiomyopathy in a human subject, said method comprising:
administering to said subject, by intravenous injection or infusion or by direct administration to the heart, a gene therapy vector for expressing an exogenous nucleic acid sequence comprising:
(a) a nucleic acid sequence encoding a functional cardiac sarcomeric protein, wherein said cardiac sarcomeric protein is cardiac myosin binding protein C (cMyBP-C), and
(b) a cardiomyocyte-specific promoter which is operably linked to said nucleic acid sequence,
wherein said gene therapy vector is an adeno-associated virus vector, wherein said subject carries a mutation in a gene encoding said cardiac sarcomeric protein which expresses a level of non-functional mutant versions of said protein and causes said hypertrophic cardiomyopathy, and wherein after said administering, said exogenous nucleic acid sequence expresses said functional cardiac sarcomeric protein in the subject and the level of non-functional mutant versions of said protein is reduced in the subject.
2. The method of claim 1 , wherein said cardiomyocyte-specific promoter is the human cardiac troponin T promoter (hTNNT2).
3. The method of claim 2 , wherein the hTNNT2 promoter comprises the sequence of SEQ ID NO:5.
4. The method of claim 1 , wherein said cMyBP-C protein comprises the sequence of SEQ ID NO:2.
5. The method of claim 1 , wherein said vector is formulated for administration into the myocardium by intravenous or intracardiac injection or infusion.